123 related articles for article (PubMed ID: 34887751)
1. Reasons and Factors Contributing to Chinese Patients' Preference for Ustekinumab in Crohn's Disease: A Multicenter Cross-Sectional Study.
Yao L; Zhu X; Shao B; Liu R; Li Z; Wu L; Chen J; Cao Q
Front Pharmacol; 2021; 12():736149. PubMed ID: 34887751
[No Abstract] [Full Text] [Related]
2. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
[TBL] [Abstract][Full Text] [Related]
3. Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn's Disease on Ustekinumab: A Nationwide Real-World Study.
Liu R; Li Z; Ye L; Hu J; Tang J; Chen B; Chen X; Tan B; Gu Y; Xie C; Ouyang C; Song X; Li F; Fan Y; Ren H; Zhu L; Chen M; Jiang W; Cao Q
Inflamm Bowel Dis; 2024 Jan; 30(1):45-52. PubMed ID: 36880432
[TBL] [Abstract][Full Text] [Related]
4. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab Therapeutic Drug Monitoring-Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial.
Afif W; Sattin B; Dajnowiec D; Khanna R; Seow CH; Williamson M; Karra K; Wang Y; Gao LL; Bressler B
Dig Dis Sci; 2022 Jul; 67(7):3148-3157. PubMed ID: 34401983
[TBL] [Abstract][Full Text] [Related]
6. A bibliometric and visual analysis of the use of ustekinumab in Crohn's disease using CiteSpace.
Chen Y; Zhang J; Wu J; Zhang H; Luan Z; Zhao Z; Li C; Zhao Y; Zhang H; Wang S; Sun G
Front Pharmacol; 2023; 14():1322319. PubMed ID: 38269276
[No Abstract] [Full Text] [Related]
7. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
8. P066 Real-World Experience of Ustekinumab in Crohn's Disease Patients With Prior Anti-TNF Therapy at a Tertiary Care Hospital.
Tripathi K; Groudan K; Chalhoub J; Yedla A; Singhania R
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17. PubMed ID: 37461983
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study.
Albshesh A; Taylor J; Savarino EV; Truyens M; Armuzzi A; Ribaldone DG; Shitrit AB; Fibelman M; Molander P; Liefferinckx C; Nancey S; Korani M; Rutka M; Barreiro-de Acosta M; Domislovic V; Suris G; Eriksson C; Alves C; Mpitouli A; di Jiang C; Tepeš K; Coletta M; Foteinogiannopoulou K; Gisbert JP; Amir-Barak H; Attauabi M; Seidelin J; Afif W; Marinelli C; Lobaton T; Pugliese D; Maharshak N; Cremer A; Limdi JK; Molnár T; Otero-Alvarin B; Krznaric Z; Magro F; Karmiris K; Raine T; Drobne D; Koutroubakis I; Chaparro M; Yanai H; Burisch J; Kopylov U
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34209880
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
[TBL] [Abstract][Full Text] [Related]
11. A novel nomogram for predicting endoscopic remission in refractory Crohn's disease with ustekinumab administration.
Lyu S; Zhong G; Song Y; Sun Y; Li J; Fan X; Qing Q; Li M
Rev Esp Enferm Dig; 2024 Jan; ():. PubMed ID: 38236159
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab Improves Active Crohn's Disease by Suppressing the T Helper 17 Pathway.
Ihara Y; Torisu T; Miyawaki K; Umeno J; Kawasaki K; Hirano A; Fujioka S; Fuyuno Y; Matsuno Y; Sugio T; Sasaki K; Moriyama T; Akashi K; Kitazono T
Digestion; 2021; 102(6):946-955. PubMed ID: 34350861
[TBL] [Abstract][Full Text] [Related]
13. Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).
Kim ES; Kim KO; Jang BI; Lee CK; Kim HJ; Lee KM; Kim YS; Eun CS; Jung SA; Yang SK; Lee J; Kim TO; Jung Y; Seo GS; Yoon SM;
Gut Liver; 2016 May; 10(3):391-8. PubMed ID: 26347512
[TBL] [Abstract][Full Text] [Related]
14. Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease.
He M; Li C; Tang W; Kang Y; Zuo Y; Wang Y
Immun Inflamm Dis; 2021 Dec; 9(4):1529-1540. PubMed ID: 34469062
[TBL] [Abstract][Full Text] [Related]
15. Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort.
Kubesch A; Rueter L; Farrag K; Krause T; Stienecker K; Hausmann J; Filmann N; Dignass A; Stein J; Blumenstein I
J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817134
[No Abstract] [Full Text] [Related]
16. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
[TBL] [Abstract][Full Text] [Related]
18. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study.
Shim HH; Ma C; Kotze PG; Seow CH; Al-Farhan H; Al-Darmaki AK; Pang JXQ; Fedorak RN; Devlin SM; Dieleman LA; Kaplan GG; Novak KL; Kroeker KI; Halloran BP; Panaccione R
J Can Assoc Gastroenterol; 2018 Sep; 1(3):115-123. PubMed ID: 31294352
[TBL] [Abstract][Full Text] [Related]
19. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real-world data analysis.
Banon T; Weil C; Borsi A; Chodick G; Shakked Z; Barit Ben-David N
JGH Open; 2022 Feb; 6(2):120-125. PubMed ID: 35155821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
